Exact Sciences is set to acquire Johns Hopkins spinout Thrive Earlier Detection for up to $2.15bn in cash and stock, including $1.7bn upfront.

Thrive Earlier Detection, a US-based cancer screening technology spinout of Johns Hopkins University, yesterday agreed to an acquisition by molecular diagnostics company Exact Sciences, one of its existing backers, for up to $2.15bn. The transaction consists of cash and stock, and Exact Sciences will pay $1.7bn upon the deal’s closure. The $1.7bn upfront payment will…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.